Full-Service Law Firm solving complex challenges through bold thinking, precise execution, and shared purpose.

Full Service Law Firm | Michael Best & Friedrich LLP

Specializing in the Intersection of Business &amp; Government

Meet our team of trusted advisors, strategic thinkers, and community builders dedicated to client success.

Learn about our full-service legal and business solutions, designed to address complex challenges for leading organizations across industries.

Access thought leadership, news, and resources to stay informed about the latest trends, legal developments, and industry innovations.

Discover how partnership, bold thinking, and precise execution drive results for clients nationwide.

Explore how our national reach and local expertise support clients across the United States and beyond.

Grow at a firm designed to bring out your best.

GLP-1 agonist medications are not a new category—they were first developed in the late 2010s to treat diabetes. However, they are currently gaining significant attention for their potential health benefits in treating overweight and obese patients. Originally developed for managing type 2 diabetes, these medications help regulate blood sugar levels by stimulating insulin production and suppressing glucagon secretion. Recent studies have highlighted their effectiveness in promoting weight loss, as they also reduce appetite and slow gastric emptying. The American Diabetes Association reports that GLP-1 agonists can lead to an average weight loss of 5-10% of body weight over six months (American Diabetes Association, 2023). However, their use in treating obesity has raised concerns about potential harms, including high rates of weight regain when patients discontinue the medication and side effects such as nausea, vomiting, and pancreatitis.

core/paragraph

The popularity of GLP-1 agonists for weight loss has significant cost implications for health plans and the healthcare system overall. The high demand for these medications, driven by their off-label use for weight management, has led to increased expenditures. According to a report from the Journal of the American Medical Association, the annual cost of GLP-1 agonists can exceed $10,000 per patient, contributing to the rising costs of prescription medications (JAMA, 2023). Additionally, the potential for supply shortages exacerbates these financial burdens, as gaps in medication availability can lead to treatment interruptions and subsequent weight regain, complicating patient management and further driving up healthcare costs.

Health plans are taking proactive steps to mitigate these potential harms and manage the high costs associated with GLP-1 agonists by partnering with third-party apps for companion and step-down programs. These digital tools offer personalized guidance, dietary recommendations, and exercise plans to help maintain weight loss and reduce the risk of rebound weight gain. Continuous patient engagement through these apps ensures adherence to lifestyle modifications, enhancing the overall effectiveness of treatment. From the health plan's perspective, these partnerships provide a cost-effective solution to support patient health while potentially reducing long-term expenditures associated with chronic weight management. By leveraging innovative technologies and third-party expertise, health plans can optimize patient outcomes, streamline care processes, and address the challenges associated with the widespread use of GLP-1 agonists in treating obesity.

<a href="https://michaelbest.healthcare/healthcare-innovation-group/?utm_source=Email&amp;utm_medium=send&amp;utm_id=MBS+Snaps&amp;utm_content=1#PROVIDERSPROCESS" target="_blank" rel="noopener">Learn more</a> about how we simplify discovering and implementing innovative solutions.

Blue-toned scientific background featuring laboratory glassware overlaid with chemical structures and a periodic table.

Tech-Driven Innovations in Action: GLP Agonists

You may also be interested in these

Does Your Church Need a Bag Policy? What Size, What Standard, and Why It Matters Now?

Emergency Declaration Targets Foreign-Produced Bulk Power Grid Equipment: Executive Order 14420

OFCCP Finalizes Major Changes to Federal Contractor Affirmative Action Regulations

You may also be interested in these

Does Your Church Need a Bag Policy? What Size, What Standard, and Why It Matters Now?

Emergency Declaration Targets Foreign-Produced Bulk Power Grid Equipment: Executive Order 14420

OFCCP Finalizes Major Changes to Federal Contractor Affirmative Action Regulations

Slide Menu

Slide Search